FindTrial
Sign In

MSB0011359C

DRUG3 trials

Sponsors

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany, National Cancer Institute (NCI)

Conditions

Colorectal CancersSmall Bowel CancersSolid Tumors

Phase 1

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
CompletedNCT02517398
EMD Serono Research & Development Institute, Inc.Solid Tumors
Start: 2015-08-31End: 2022-05-23Updated: 2024-05-03
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
CompletedNCT02699515
Merck KGaA, Darmstadt, GermanySolid Tumors
Start: 2016-03-11End: 2022-02-21Updated: 2024-11-18

Phase 2

Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
CompletedNCT04491955
National Cancer Institute (NCI)Colorectal Cancers, Small Bowel Cancers
Start: 2020-09-22End: 2024-08-16Updated: 2025-04-24

Related Papers

The Quadruple Immunotherapy for Colorectal Cancer (QuICC) Trial for Mismatch Repair-Proficient Metastatic Colorectal Cancer.
2026-01-10
Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC
Hepatology2024-08-135 citations
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer
Journal for ImmunoTherapy of Cancer2024-03-0112 citations
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer
Clinical Cancer Research2024-01-028 citations
New advances in cancer therapy targeting TGF-β signaling pathways
Molecular Therapy — Oncolytics2023-12-0127 citations
Mass cytometry immune profiling to detect signatures of clinical activity of bintrafusp alfa (BA) in patients with advanced non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2023-06-01
Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers.
Journal of Clinical Oncology2023-01-243 citations
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
The Oncologist2022-12-2823 citations
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
The Oncologist2022-12-2633 citations
Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer
Frontiers in Oncology2022-12-085 citations
Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.
2022-11-24186 citations
Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1.
2022-09-0615 citations
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
Journal for ImmunoTherapy of Cancer2021-11-01
116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
Cervical cancer2021-10-01
Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies.
Journal of Clinical Oncology2021-05-2015 citations
Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).
Journal of Clinical Oncology2021-05-207 citations
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
2021-05-1937 citations
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
2021-04-1123 citations
A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer.
Journal of Clinical Oncology2021-02-203 citations
Abstract OT-32-01: A phase 2, open-label study of bintrafusp alfa monotherapy in patients with <i>HMGA2</i>-expressing triple-negative breast cancer
Cancer Research2021-02-15

35 more papers not shown